Targovax: Targovax is a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors. Targovax’s lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus that has been engineered to selectively infect and replicate in cancer cells. It has been shown to activate the immune system to generate tumor-specific immune responses. ONCOS-102’s targeted path-to-market indication is mesothelioma, where the virus is currently being tested in a randomized phase II trial.
Based in...
Clinical Stage
Phase l or ll
Disease Space
Anti-infectives, Antivirals, Immuno-Oncology, Immunotherapy, Oncology
Europe, Public
Market Cap
Therapeutic Modalities
Platform Technology
Lilleakerveien 2 C
Oslo, NO-0283

Company Participants at Solebury Trout Annual 1x1 Management Access Event

Erik Digman Wiklund
Targovax, Chief Business Officer
Former consultant in the Pharma & Healthcare practice of McKinsey & Company, combined with a PhD in cancer research Erik brings experience from management consulting, as well as commercial and operational roles in the biotechnology industry. Most recently he held the position as Director of Product Innovation in the nutraceutical company Aker Biomarine Antarctic AS, and also has experience from the Norwegian oncology success Algeta ASA. Erik holds a PhD in Molecular Biology from Aarhus University, Denmark, and the Garvan Institute in Sydney, Australia.
Torbjørn Furuseth
Targovax, Chief Financial Officer
An experienced executive with a broad background within life science. He joins from the clinical stage immune-oncology company Lytix Biopharma, where he has served as CFO and conducted several financing rounds. Prior to this, he was EVP Innovation at Aker BioMarine, where he established and led the innovation department. Torbjørn also brings six years’ experience as a management consultant at McKinsey & Company, where he served several pharma and healthcare clients. Torbjørn is a Medical Doctor from Norwegian University of Science and Technology (NTNU).
Øystein Soug
Targovax, CEO
20 years in international banking and industry, the last six of which as CFO of Algeta ASA and was the former CFO of Targovax ASA. Øystein Soug is the former CFO of Algeta, a Norwegian oncology biotech company which was sold to Bayer for USD 2.9 billion in 2014. Prior to joining Algeta in 2008 Mr. Soug worked for six years at Orkla, lastly as CFO of Orkla’s Russian division. Mr. Soug started his career as a banker with Credit Suisse and with the European Bank for Reconstruction and Development. Mr. Soug received an MSc in Economics and Financial Markets from Universität St. Gallen in Switzerland in 1997.

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

European Biotech Investor Day 2019

New York City, August 1, 2019

Hamptons CEO Roundtable 2019

Bridgehampton, August 15, 2019

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2017 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.